Loading...
Loading...
Browse all stories on DeepNewz
VisitWhat will be the outcome of Phase 3 trial for V940 and KEYTRUDA in NSCLC by end of 2025?
Positive - Significant survival improvement • 25%
Neutral - No significant difference • 25%
Negative - Worse outcomes • 25%
Trial inconclusive • 25%
Published trial results in medical journals or company press releases
Merck and Moderna Launch Phase 3 Trial for V940 and KEYTRUDA in Lung Cancer Treatment
Oct 28, 2024, 10:47 AM
Merck and Moderna have initiated a Phase 3 trial to evaluate the efficacy of their investigational individualized neoantigen therapy, V940 (mRNA-4157), in combination with KEYTRUDA (pembrolizumab) and immunotherapy for patients with certain types of non-small cell lung cancer (NSCLC). This trial follows the use of neoadjuvant KEYTRUDA and chemotherapy. The adjuvant mRNA vaccine, a cousin to the COVID-19 vaccines, has entered human trials as a treatment for lung cancer. This marks the third Phase 3 trial for the V940 cancer vaccine and the second specifically targeting early-stage lung cancer.
View original story
Significant tumor shrinkage • 25%
Improved survival rates • 25%
No significant effect • 25%
Other • 25%
Exceeds regulatory criteria • 25%
Meets regulatory criteria • 25%
Fails to meet regulatory criteria • 25%
Trial delayed or inconclusive • 25%
Significant survival improvement • 25%
Partial survival improvement • 25%
No significant change • 25%
Deterioration • 25%
Successful with significant improvement in survival rates • 25%
Successful with moderate improvement in survival rates • 25%
No significant improvement in survival rates • 25%
Trial halted due to adverse effects • 25%
Yes • 50%
No • 50%
Meets primary endpoint • 25%
Fails primary endpoint • 25%
Mixed results • 25%
Trial not completed by end of 2025 • 25%
Complete Response • 25%
Partial Response • 25%
Stable Disease • 25%
Progressive Disease • 25%
Trial Resumed • 33%
Trial Terminated • 33%
Trial Modified • 34%
Positive efficacy and safety results • 25%
Positive efficacy, but safety concerns • 25%
Negative efficacy, but good safety • 25%
Negative efficacy and safety concerns • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Significant Improvement • 33%
No Change • 33%
Significant Adverse Effects • 34%
Approved • 25%
Not Approved • 25%
Pending • 25%
Withdrawn • 25%
Yes • 50%
No • 50%
Merck stock rises • 25%
Neither stock rises • 25%
Both stocks rise • 25%
Moderna stock rises • 25%